GlassScriptPhysician profile
Elizabeth Burtman
NPI 1679866255
$10,481.47
in general payments reported to CMS, 2019-2025
27 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $474 · 2021: $866 · 2022: $1,117 · 2023: $4,865 · 2024: $1,740 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331 · Consulting Fee: $3,060 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $740 · Travel and Lodging: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,331.38 |
| Consulting Fee | $3,060.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $740.00 |
| Travel and Lodging | $455.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,976.79 | 2019-2025 | |
| Abbvie INC. | $1,575.67 | 2019-2025 | Lupron Depot, Synthroid |
| Novo Nordisk INC | $1,331.36 | 2019-2025 | Sogroya, Wegovy, Norditropin |
| Ascendis Pharma Endocrinology INC | $507.76 | 2022-2025 | Skytrofa |
| Amneal Pharmaceuticals LLC | $306.20 | 2021-2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $182.98 | 2023-2025 | Imcivree, Imcivree |
| Sandoz INC. | $163.22 | 2020-2025 | Omnitrope |
| Tolmar Pharmaceuticals, INC. | $149.31 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $135.23 | 2019-2022 | |
| Tolmar, INC. | $127.92 | 2023-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $121.35 | 2024 | |
| Arbor Pharmaceuticals, INC. | $107.54 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $102.81 | 2023-2025 | Triptodur, Triptodur |
| Intra-Sana Laboratories | $100.00 | 2022 | |
| Endo USA, INC. | $95.82 | 2025 | Supprelin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $82.80 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $78.15 | 2023-2024 | Voxzogo 1.2mg |
| Ibsa Pharma INC. | $71.57 | 2019-2024 | Tirosint, Licart, Licart |
| Soleno Therapeutics, INC. | $69.44 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $48.10 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $44.73 | 2021-2025 | Strensiq |
| Neurocrine Biosciences, INC. | $31.51 | 2024-2025 | |
| Vivus LLC | $17.25 | 2023 | Qsymia |
| Kyowa Kirin, INC. | $16.94 | 2024 | Crysvita |
| Galderma Laboratories, L.P. | $12.45 | 2019 | |
| Dexcom, INC. | $12.29 | 2021 | |
| Lilly USA, LLC | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Burtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.